Hostname: page-component-77c89778f8-swr86 Total loading time: 0 Render date: 2024-07-16T17:36:17.118Z Has data issue: false hasContentIssue false
  • English
  • Français

Cytotoxic agents and radiation therapy: mechanisms of action and clinical applications

Published online by Cambridge University Press:  17 October 2014

Amanda Marrone  and
William T. Tran
Amanda Marrone*
Affiliation:
Department of Radiation Therapy, Royal Victoria Hospital, Barrie, ON, Canada
William T. Tran
Affiliation:
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
*
Correspondence to: Amanda Marrone, Department of Radiation Therapy, 201 Georgian Drive, The Royal Victoria Hospital, Barrie, L4M 6M2 ON, Canada. Tel: (705) 728 9802, Ext. 43425. E-mail: marronea@rvh.on.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

The combination of radiation therapy and chemotherapy is rooted in its ability to help achieve locoregional and systemic control, therefore increasing the overall disease-free survival of patients. Understanding the mechanistic actions of cytotoxic agents and their targets on the cell cycle, as well as the governing pharmacokinetic principles can improve treatment delivery. The adjuvant treatment setting can overcome barriers such as hypoxia and genetically driven treatment resistance.

Purpose

The purpose of this review is to present theoretical frameworks behind the chemoradiation paradigm and to describe current chemoradiation practices in radiation oncology.

Methodology

A review was conducted using the US National Library of Medicine, National Institutes of Health database (PubMed) using the following search keywords: chemoradiation, spatial cooperation, chemotherapeutic agents, pharmacokinetics, anti-vascular agents, tumour vasculature and tumour hypoxia.

Results and conclusions

Current research has reported several rationales for the beneficial combination of radiation and chemotherapy to eradicate oncological diseases. Mechanisms of action and biological approaches are showing that concurrent treatments, as well as novel agents such as anti-vascular and anti-angiogenic agents may benefit improved treatment outcomes by reducing micro hypoxic environments in tumours. In addition, chemotherapy administered in tandem with radiation enhances cell-killing effects by targeting the cell cycle.

Keywords

chemoradiationchemotherapeutic agentsspatial cooperationtumour hypoxiatumour vasculature
Type
Literature Reviews
Information
Journal of Radiotherapy in Practice , Volume 14 , Issue 1 , March 2015 , pp. 63 - 69
Copyright
© Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Seiwert, T Y, Salama, J K, Vokes, E E. The concurrent chemoradiation paradigm—general principles. Nat Clin Pract Oncol 2007; 4 (2): 86–100.CrossRefGoogle ScholarPubMed
2.Bentzen, S M, Harari, P M, Bernier, J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 2007; 4 (3): 172–180.Google Scholar
3.Steel, G G, Peckham, M J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979; 5 (1): 85–91.Google Scholar
4.Tran, W T, El Kaffas, A, Al-Mahrouki, A, Gillies, C, Czarnota, G J. A review of vascular disrupting agents as a concomitant anti-tumour modality with radiation. J Radiother Pract 2013; 12 (3): 255–262.Google Scholar
5.Nishimura, Y. Rationale for chemoradiotherapy. Int J Clin Oncol 2004; 9 (6): 414–420.CrossRefGoogle ScholarPubMed
6.Tozer, G M, Kanthou, C, Baguley, B C. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5 (6): 423–435.Google Scholar
7.Shannon, A M, Bouchier-Hayes, D J, Condron, C M, Toomey, D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 2003; 29 (4): 297–307.CrossRefGoogle ScholarPubMed
8.Wachsberger, P, Burd, R, Dicker, A P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003; 9 (6): 1957–1971.Google Scholar
9.Hall, J, Giaccia, A. Radiobiology for the Radiologist. Philadelphia, PA: Lippincott Williams & Wilkins, 2006.Google Scholar
10.Rockwell, S, Dobrucki, I T, Kim, E Y, Marrison, S T, Vu, V T. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 2009; 9 (4): 442–458.CrossRefGoogle ScholarPubMed
11.Harrison, L, Blackwell, K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004; 9 (suppl 5): 31–40.Google Scholar
12.Tozer, G M, Bicknell, R. Therapeutic targeting of the tumor vasculature. Semin Radiat Oncol 2004; 14 (3): 222–232.CrossRefGoogle ScholarPubMed
13.Ralhan, R, Kaur, J. Alkylating agents and cancer therapy. Expert Opin Ther Patents 2007; 17 (9): 1061–1075.Google Scholar
14.Scagliotti, G V, Selvaggi, G. Antimetabolites and cancer: emerging data with a focus on antifolates. Expert Opin Ther Patents 2006; 16 (2): 189–200.CrossRefGoogle ScholarPubMed
15.Gez, E, Sulkes, A, Yablonsky-Peretz, T. Combined 5-fluorouracil (5-FU) and radiation therapy following resection of locally advanced gastric carcinoma. J Surg Oncol 1986; 31: 139–142.Google Scholar
16.Kvols, L K. Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets. J Nucl Med 2005; 46 (1): 187S–190S.Google Scholar
17.Lawerence, T S, Blackstock, A W, McGinn, C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003; 13 (1): 13–21.CrossRefGoogle Scholar
18.Frame, D. Introduction to taxane pharmacokinetics and pharmacodynamics. J Oncol Pharm Pract 2000; 6 (3): S22–S27.Google Scholar
19.Stupp, R, Mason, W P, van den Bent, M Jet al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–996.CrossRefGoogle ScholarPubMed
20.Brada, M, Judson, I, Beale, Pet al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999; 81 (6): 1022–1030.Google Scholar
21.Portnow, J, Badie, B, Chen, M, Liu, A, Blanchard, S, Synold, T W. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 2009; 15 (22): 7092–7098.Google Scholar
22.Yu, C K, Kim, T W, Kim, J Het al. Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 67 (4): 1020–1026.CrossRefGoogle ScholarPubMed
23.Rose, P G, Bundy, B N, Watkins, E Bet al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144–1153.Google Scholar
24.Calais, G, Alfonsi, M, Bardet, Eet al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2018–2086.Google Scholar
25.Brizel, D M, Albers, M E, Fisher, S Ret al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798–1804.Google Scholar
26.Lee, W, Brackstone, M, Gandhi, S, Arce, S C, Dinniwell, R. Salvage radiotherapy and cisplatin for triple negative breast cancer: a multi-centre study. Cancer Res 2012; 72 (24 suppl): Abstract nr P4-16-14.Google Scholar
27.Fu, K K. Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer 55: 2121–2130.Google Scholar